Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis

Xian Zhang, Qinggong Guo, Jingtao Chen, and Zhaohui Chen*

Quercetin can suppress osteosarcoma cell growth and metastasis. However, other effects of quercetin on osteosarcoma remain largely unknown. This research aims to evaluate the effects of quercetin in combination with cisplatin as treatment for osteosarcoma and investigate its regulatory mechanism. Cell viability and apoptosis in 143B cell line were determined after treatment with quercetin and/or cisplatin. RT-PCR and Western blot analysis were performed to determine the RNA or protein expression levels. Moreover, transwell assay was used to evaluate metastasis. Furthermore, rescue experiments were performed to investigate the potential regulatory mechanism of the treatment. Results showed that quercetin with concentration that was equal to or greater than 10 μM inhibited 143B proliferation, while 5 μM quercetin enhanced the cisplatin sensitivity of 143B cells. Expression of miR-217 was upregulated after quercetin and/or cisplatin treatment, while its target KRAS was downregulated both at mRNA and protein levels. MiR-217 knockdown led to the loss of enhanced cisplatin sensitivity while miR-217 overexpression showed the opposite effects, indicating that quercetin regulated cisplatin sensitivity by modulating the miR-217-KRAS axis. In conclusion, 5 μM quercetin enhanced the cisplatin sensitivity by modulating the miR-217-KRAS axis. This finding suggests that quercetin may be administered with cisplatin to improve the treatment for osteosarcoma.

INTRODUCTION

Osteosarcoma is one of the common clinical and multiple primary malignant bone tumors which damages the health of children and young adults. Multi-agent chemotherapy and primary tumor surgical resection are the most common treatments of osteosarcoma (Bielack et al., 2008). However, the common anti-neoplastic drugs, including cisplatin, doxorubicin, etoposide, ifosfamide, among others cause tolerance to chemotherapeutic agent, as well as acute/long-term toxicity (Bielack et al., 2008).

Quercetin is a flavonoid commonly found in our daily diet. Properties of quercetin, such as its being anti-inflammatory, antioxidant, anti-proliferation, and its promotion of apoptosis on cancer cells were reported (SS, 2012). Thus, owing to its anti-cancer properties, quercetin might be used as adjunctive therapy with less side effects to enhance cancer chemoprevention (Li et al., 2014; Orsolic and Car, 2014; Wang et al., 2014; Yi et al., 2014). In hepatoma, quercetin enhanced the sensitivity of cancer cells to cisplatin (Kim et al., 2008). However, in ovarian cancer cells, low concentrations of quercetin attenuate the therapeutic effects of cisplatin by reduced production of intracellular reactive oxygen species (Li et al., 2014). Studies also showed that quercetin suppresses osteosarcoma cell proliferation (Liang et al., 2011; Suh et al., 2010). However, a few researches on the effects of combined quercetin and chemotherapy on osteosarcoma, especially on their regulatory mechanism were conducted.

In this paper, we aimed to investigate the effects of quercetin combined with cisplatin, a widely used chemotherapeutic agent, as well as to investigate its regulatory mechanism.

MATERIALS AND METHODS

Cell culture and transfection

Human osteosarcoma 143B cell line was purchased from the Cell Resource Center of Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. The 143B cell lines was cultured in Dulbecco’s modified Eagle medium with 10% fetal bovine serum (Life Technologies, Germany).

The miR-217 mimic, antagonir, and siRNA of KRAS were purchased from RIBOBIO Co. Ltd (China). miR-217 mimic at 50 nM or 100 nM miR-217 antagonir was used during transfection of 143B cells by Lipofectamine 3000, purchased from Life Technologies. Ifosfamide, among others cause tolerance to chemotherapeutic agent, as well as acute/long-term toxicity (Bielack et al., 2008).

Total RNA extraction, single strand cDNA synthesis, and real-time quantitative PCR assays

Trizol method was used for all of the extraction of total RNA in this study (Ambion, USA). For single strand cDNA synthesis, 3 μg RNA was used as template and reverse transcription was performed by M-MLV (Life Science, USA). The use of real-time quantitative PCR (RT-PCR) progress and primer sequences was
 entirely adopted from the previous research (Guo et al., 2014).

**Cell proliferation, viability, and apoptosis assay**
The CCK-8 kit was used in cell proliferation or viability assay according to the user's instruction (DOJINDO, Japan). Approximately 5000 osteosarcoma cells were incubated at 37°C for 2 h in 10% CCK-8 reagent, and absorption was measured at 450 nm using micro-plate reader. For 143B apoptosis assays, apoptosis detection kit was used following the user’s instruction (BD Biosciences, USA). Cell apoptosis was detected by C6 Flow Cytometer (Thermo, USA).

**Cell migration and invasion assay**
Transwell assays were performed to evaluate the migration ability of osteosarcoma 143B cells. Approximately 5 × 10³ cells suspended in 200 µl DMEM medium without FBS was placed on the upper chamber of each transwell insert, while 600 µl DMEM with 10% FBS was placed in the lower chamber (Millipore, USA). After 24 h, migrating cells on the lower surface of the chamber were stained with 10% crystal violet. For invasion assay, 40 µl of 1 mg/ml matrigel was coated in the bottom of the chamber (Millipore, USA). The remaining processes were similar to that of the other transwell assays.

**Quercetin and cisplatin treatment**
Cisplatin was obtained from Sigma (USA). For 143B cell viability assay, 143B cells were treated with 0, 2, 4, 6, 8, 10, and 12 µM cisplatin for 24 h. About 5,000 cells were used for cell viability assay. Quercetin was purchased from Sigma (USA), and was dissolved in water with 0.5% (v/v) ethanol. Water with 0.5% ethanol was used for the control. About 20,000 cells treated with 5 µM cisplatin and 5 µM quercetin were used in the apoptosis assay.

**Western blot analysis**
Western blot analysis was performed strictly following the method described in our previous research (Guo et al., 2014).

**Statistics**
Each of the experiments in this study were performed at least three times. Student’s t-test (two-tailed) and the X² test were performed, and statistically significant level was set at α = 0.05 (two-side). Data are presented as mean ± SD.

**RESULTS**

**Quercetin equal to or greater than 10 µM inhibited viability of 143B osteosarcoma cells**
We determined the effect of varying quercetin concentrations on the viability of 143B cells. We found that 5 µM of quercetin had no significant effect on 143B viability. However, quercetin concentration of 10 µM or higher significantly reduced cell viability at 24 h or 48 h post-treatment compared with the control group (Fig. 1). This result indicated that high dose of quercetin could inhibit 143B proliferation.

**5 µM quercetin enhanced cisplatin sensitivity of 143B**
Cells of 143B line were co-treated with 5 µM quercetin and cisplatin for 24 h to determine the effect of quercetin on cisplatin sensitivity. Result revealed that cells co-treated with quercetin and cisplatin showed a cisplatin IC₅₀ of 4.21 µM indicating higher sensitivity compared with the cells treated with cisplatin alone (IC₅₀ = 6.12 µM) (Fig. 2A). In addition, 143B cells co-treated with quercetin and cisplatin exhibited significantly higher rate of early apoptosis (55.2 ± 5.61) compared with the cells treated with cisplatin alone (37.3 ± 4.67). Cells treated with quercetin alone showed no significant change in apoptosis rate (Figs. 2B and 2C). These results demonstrated that the 5 µM quercetin enhanced the cisplatin sensitivity of 143B cells.

**Quercetin enhanced cisplatin sensitivity of 143B osteosarcoma cells by modulating miR-217-KRAS axis**
Research demonstrated that miR-217 reduces cisplatin resistance by directly targeting KRAS in lung cancer cells (Guo et al., 2014). Herein, we first investigated whether a link between quercetin and miR-217-KRAS axis exists. Figure 3A shows that miR-217 in 143B cells was significantly upregulated compared with that of the control cells after quercetin or cisplatin treatment; miR-217 expression was much higher when co-treated with quercetin and cisplatin. In contrast with the miR-217 expression, downregulated KRAS expression on both mRNA and protein levels was observed (Fig. 3B). These results indicated that the miR-217-KRAS axis was involved in the response of osteosarcoma cells to quercetin.

To further confirm our hypothesis that quercetin enhances the cisplatin sensitivity of osteosarcoma cells by modulating the miR-217-KRAS axis, we determined the viability of cells subjected under different treatmets after miR-217 knockdown and overexpression (Figs. 3C and 3D). Cells both transfected with miR-217 mimic and treated with quercetin elicited the sensitivity of osteosarcoma cells. Viability of miR-217 mimic-transfected cells treated with quercetin was significantly lower than that of the cells transfected with miR-217 mimic only or treated with quercetin alone. By contrast, osteosarcoma cells transfected with miR-217 antagonim showed resistance to cisplatin, which could be partly abated by quercetin treatment. These results demonstrated that quercetin enhanced cisplatin sensitivity of osteosarcoma cells by regulating miR-217 expression. In addition, result of Western blot analysis confirmed that miR-217 targeted KRAS of 143B cells (Fig. 4A). The proliferation, migration, and invasion of 143B cells were suppressed resulting from overexpression of miR-217; the opposite effects were observed when miR-217 was knocked down by antagonim (Figs. 4B-4D). These results further demonstrated that quercetin regulated the cisplatin sensitivity osteosarcoma cells by modulating the miR-217-KRAS axis.
DISCUSSION

Cisplatin is widely used as a chemotherapeutic agent, and the effects of which on osteosarcoma have been proven (Chou et al., 2013; Martinez-Velez et al., 2014). After cisplatin treatment, many patients unfortunately experience recurrence of cancer, which become refractory to subsequent chemotherapy. This is a big challenge in chemotherapy treatment of osteosarcoma. However, cisplatin resistance in every cancer type including osteosarcoma appears to be the result of multiple and complex mechanisms.
Quercetin Enhances Cisplatin Sensitivity in Osteosarcoma
Xian Zhang et al.

Quercetin is a potential anticancer agent which enhances cancer chemoprevention. Synergistic anti-tumor activities of cisplatin and quercetin have long been reported in cancer treatment (Scambia et al., 1990). In vivo studies showed that quercetin modulates DNA damage induced by cisplatin in neoplastic tissue and normal tissue (Orsolic and Car, 2014). PI3K/Akt pathway is a classical pathway modulating cisplatin resistance, thus influencing cisplatin resistance in osteosarcoma (Zhao et al., 2013). Through mitochondrial dysfunction and dephosphorylation of Akt, quercetin induces apoptosis in methotrexate-resistant osteosarcoma cancer cells (Xie et al., 2011).

In this study, we initially verified that the effects of quercetin on osteosarcoma depend on its working concentration. 5 μM quercetin showed no inhibiting effect on osteosarcoma, but it significantly increased the cytotoxic effect of cisplatin. However, high quercetin dose (≥ 10 μM) directly suppressed 143B osteosarcoma cell growth, a result which is parallel with that of previous research (Berndt et al., 2013).

We previously demonstrated in our laboratory that tumor suppressor miR-217 reduces cisplatin resistance in lung cancer by negatively regulating the KRAS-Akt axis. Results in this study support the conclusion that miR-217 targets the KRAS in osteosarcoma. Interestingly, miR-217 plays contrasting roles in cancer depending on cancer type (Kato et al., 2009; Zhao et al., 2010). Herein, miR-217 is a tumor suppressor which inhibits cell proliferation and metastasis in osteosarcoma. In addition, it was demonstrated herein that miR-217 was upregulated by quercetin treatment. Meanwhile, to verify the correlation among quercetin treatment, miR-217 expression, and 143B cisplatin sensitivity, we performed rescue experiments by overexpressing or knocking down miR-217 expression. Result showed that quercetin caused cisplatin sensitivity was offset by miR-217 knockdown. Overexpression of miR-217 showed similar effect as that of quercetin treatment, although higher cisplatin sensitivity was observed in 143B cells. Thus, these results confirmed that low quercetin dose (5 μM) upregulated miR-217, which directly targeted KRAS that, in turn, negatively regulated the PI3K/AKT pathway, thereby suppressing cisplatin resistance in osteosarcoma. Quercetin enhances the cisplatin sensitivity of osteosarcoma.
Quercetin Enhances Cisplatin Sensitivity in Osteosarcoma
Xian Zhang et al.

haptoma cells (Kim et al., 2008). However, 5 μM quercetin concentrations reduce the production of intracellular reactive oxygen species, thereby weakening the therapeutic effects of cisplatin in ovarian cancer cells (Li et al., 2014). These findings suggest that quercetin plays multiple roles depending on the type of cancer.

This study mainly demonstrated three points. First, enhanced cisplatin sensitivity in osteosarcoma cell was mediated by 5 μM quercetin, while equal to or greater than 10 μM quercetin directly inhibited 143B cells. Second, we proved that miR-217 is a tumor suppressor which promoted apoptosis and suppressed proliferation and metastasis of osteosarcoma cells. Third, quercetin enhanced the cisplatin sensitivity of osteosarcoma cells by modulating the miR-217-KRAS axis. These results not only elucidated the functions and mechanism of quercetin in regulating the resistance of cancer to chemotherapeutic, but also provided valuable information on a potential novel targeted drug combinations against osteosarcoma.

ACKNOWLEDGMENTS
The authors would like to thank Dr. Junhua Guo for extending excellent technical assistance and for his valuable suggestions in the design of the experiment. This study was supported by the National Natural Science Foundation of China (81371981). We declare no conflict of interest.

REFERENCES

Berndt, K., Campanile, C., Muff, R., Strehler, E., Born, W., and Fuchs, B. (2013). Evaluation of quercetin as a potential drug in osteosarcoma treatment. Anticancer Res. 33, 1297-1306.

Bielack, S.S., Carle, D., Hardes, J., Schuck, A., and Paulussen, M. (2008). Bone tumors in adolescents and young adults. Curr. Treat Options Oncol. 9, 67-80.

Chou, A.J., Gupta, R., Bell, M.D., Riewe, K.O., Meyers, P.A., and Paulussen, M. (2008). Bone tumors in adolescents and young adults. Curr. Treat Options Oncol. 9, 67-80.

Chow, J.H., Peng, Z.J., Huang, Z., Wang, H.Y., and Lu, W.J. (2014). Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. PLoS One 9, e100314.

Liang, W., Li, X., Li, C., Liao, L., Gao, B., Gan, H., Yang, Z., and Chen, X. (2011). Quercetin-mediated apoptosis via activation of the mitochondrial-dependent pathway in MG-63 osteosarcoma cells. Mol. Med. Rep. 4, 1017-1023.

Martinez-Velez, N., Xipell, E., Jauregut, P., Zalacain, M., Marrodan, L., Zandueta, C., Vera, B., Urquiza, L., Sierrasausamaga, L., Julian, M.S., et al. (2014). The oncolytic adenovirus Delta24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity. J. Bone Miner Res. 29, 2287-2296.

Orsolic, N., and Car, N. (2014). Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo. Cell Biol. Int. 38, 1836-1843.

Scambia, G., Ranelletti, F.O., Benedetti Panici, P., Bonanno, G., De Vincenzo, R., Piantelli, M., and Mancuso, S. (1990). Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anticancer Drugs 1, 45-48.

Shen, D.W., Poulot, L.M., Hall, M.D., and Gottesman, M.M. (2012). Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64, 706-721.

SS, B. (2012). A review of quercetin: Antioxidant and anticancer properties. World J. Pharm. Pharm. Sci. 1, 146-160.

Suh, D.K., Lee, E.J., Kim, H.C., and Kim, J.H. (2010). Induction of G1/S phase arrest and apoptosis by quercetin in human osteosarcoma cells. Arch. Pharm. Res. 33, 781-785.

Wang, P., Vadgama, J.V., Said, J.W., Magyar, C.E., Doan, N., Heber, D., and Henning, S.M. (2014). Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea. J. Nutr. Biochem. 25, 73-80.

Wu, J., Liao, Q., He, H., Zhong, D., and Yin, K. (2014). TWIST interacts with beta-catenin, signaling on osteosarcoma cell survival against cisplatin. Mol. Carcinog. 53, 440-446.

Xie, X.B., Yin, J.Q., Jia, Q., Wang, J., Zou, C.Y., Brewer, K.J., Colombo, C., Wang, Y.F., Huang, G., and Shen, J.N. (2011). Quercetin induces apoptosis in the methotrexate-resistant osteosarcoma cell line U2-OS/MTX300 via mitochondrial dysfunction and dephosphorylation of akt. Oncol. Rep. 26, 687-693.

Yi, L., Zongyuan, Y., Cheng, G., Lingyun, Z., Guilian, Y., and Wei, G. (2014). Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 105, 520-527.

Zhao, W.G., Yu, S.N., Lu, Z.H., Ma, Y.H., Gu, Y.M., and Chen, J. (2010). The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31, 1726-1733.

Zhao, G.Y., Bai, C.K., Yang, T.T., Qiu, X.C., Liao, B., Li, W., Ji, Z.W., Zhao, J., Zhao, H.E., Guo, M.J., et al. (2013). MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One 8, e53906.